Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-D-2839

Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability

Documents

Comments

Description

OPEN

Key Dates

Comment Period OpensJun 1, 2026

Comment Period ClosesAug 1, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Guidance for Industry - Draft Guidance	Jun 1, 2026	43

Comment Statistics

Total Comments

Keywords

CDER

2025-503

Guidance for Industry

Oncology Pharmaceuticals

Streamlined Nonclinical Safety

Studies for Biologics and Conjugated Products

OPEN

Data from Regulations.gov